Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FYN | P06241 | 15/20 | 0.55 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.38 |
| ▸ | KCNN4 | O15554 | 2/20 | 0.35 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.34 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.33 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.33 |
| ▸ | PRKD2 | Q9BZL6 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10100579 | 0.91 | FYN (0.45) | FYNKCNN4 | |
| SCHEMBL10100542 | 0.91 | FYN (0.44) | FYNCHEK2KCNN4TLR7 | |
| SCHEMBL10100502 | 0.91 | FYN (0.45) | FYNKCNN4 | |
| SCHEMBL10100551 | 0.91 | FYN (0.43) | FYNCHEK2KCNN4TLR7PRKD3 | |
| SCHEMBL10100533 | 0.90 | FYN (0.43) | FYNCHEK2TLR7 | |
| SCHEMBL10100765 | 0.86 | FYN (0.45) | FYNKCNN4 | |
| SCHEMBL10100529 | 0.86 | FYN (0.46) | FYNCHEK2PRKD3PRKD1PRKD2 | |
| SCHEMBL10100564 | 0.86 | FYN (0.42) | FYN | |
| SCHEMBL10100526 | 0.86 | FYN (0.39) | FYNCHEK2KCNN4TLR7 | |
| SCHEMBL10100539 | 0.85 | FYN (0.46) | FYNCHEK2KCNN4TLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8518938-B2 | c-MET protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-08-27 | — | — | US | disclosed |
| US-8518938-B2 | c-MET protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-08-27 | — | — | US | disclosed |
| US-20120165333-A1 | C-MET PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-06-28 | — | — | US | disclosed |
| US-20120165333-A1 | C-MET PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165333-A1 | C-MET PROTEIN KINASE INHIBITORS | MET, PRKCH, ABL1 | FYN 532/4885CHEK2 109/4885KCNN4 4066/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.